Gene-Editing Startup Aims to Revolutionize Treatment for Rare Diseases with Crispr Technology
A new startup, Aurora Therapeutics, co-founded by Nobel Prize-winning scientist Jennifer Doudna, is working on developing tailored gene-editing treatments for patients with rare diseases. The company plans to use a new FDA regulatory pathway that allows the approval of personalized therapies based on data from just a handful of patients.
Currently, the development and approval process for new drugs requires testing in hundreds or thousands of patients, making it challenging to recruit participants for rare disease trials. However, the new FDA pathway provides a way for these types of treatments to be approved when a large, randomized trial isn't possible.
Aurora Therapeutics aims to tackle a metabolic disorder called phenylketonuria (PKU), which is screened for at birth and can lead to toxic levels of phenylalanine in the blood if left untreated. Patients with PKU must follow a highly restrictive low-protein diet, and without early treatment and monitoring, it can hinder brain development and impair cognitive functions.
The company's strategy involves using base editing, a more precise form of Crispr gene editing, to create several versions of a PKU therapy that address different mutations. This approach will allow Aurora to treat many patients with the disease with less regulatory red tape compared to traditional approaches.
Aurora's goal is to provide treatment options for those who currently have limited or no access to effective therapies. The company is already making progress, having successfully treated a sick infant named KJ with a bespoke gene-editing therapy that corrected his specific genetic mutation.
While Crispr technology has yet to fully live up to its transformative potential, experts believe that the field is turning a corner as the technology matures. With continued advancements and refinements, it's likely that Crispr-based treatments will become more widespread in the coming years.
The Innovative Genomics Institute, which Doudna established in 2015, will continue to create bespoke gene-editing therapies for children with rare diseases, while a trial at the Children's Hospital of Philadelphia and Penn Medicine will test the same type of gene editor used in KJ's therapy in a group of similar disorders.
A new startup, Aurora Therapeutics, co-founded by Nobel Prize-winning scientist Jennifer Doudna, is working on developing tailored gene-editing treatments for patients with rare diseases. The company plans to use a new FDA regulatory pathway that allows the approval of personalized therapies based on data from just a handful of patients.
Currently, the development and approval process for new drugs requires testing in hundreds or thousands of patients, making it challenging to recruit participants for rare disease trials. However, the new FDA pathway provides a way for these types of treatments to be approved when a large, randomized trial isn't possible.
Aurora Therapeutics aims to tackle a metabolic disorder called phenylketonuria (PKU), which is screened for at birth and can lead to toxic levels of phenylalanine in the blood if left untreated. Patients with PKU must follow a highly restrictive low-protein diet, and without early treatment and monitoring, it can hinder brain development and impair cognitive functions.
The company's strategy involves using base editing, a more precise form of Crispr gene editing, to create several versions of a PKU therapy that address different mutations. This approach will allow Aurora to treat many patients with the disease with less regulatory red tape compared to traditional approaches.
Aurora's goal is to provide treatment options for those who currently have limited or no access to effective therapies. The company is already making progress, having successfully treated a sick infant named KJ with a bespoke gene-editing therapy that corrected his specific genetic mutation.
While Crispr technology has yet to fully live up to its transformative potential, experts believe that the field is turning a corner as the technology matures. With continued advancements and refinements, it's likely that Crispr-based treatments will become more widespread in the coming years.
The Innovative Genomics Institute, which Doudna established in 2015, will continue to create bespoke gene-editing therapies for children with rare diseases, while a trial at the Children's Hospital of Philadelphia and Penn Medicine will test the same type of gene editor used in KJ's therapy in a group of similar disorders.